

Germany's Profos AG, a worldwide supplier of biotechnology products for the food diagnostic, life science, biotechnology and pharmaceutical industries, is gearing up for an important appearance at Analytica 2008 (April 1-4 in Munich, Germany). Profos will spotlight its EndoGrade™ Ovalbumin, an ultra high-quality ovalbumin for *in vivo* and *in vitro* immunological studies that virtually eliminates the problem of contamination with elevated endotoxin levels that frequently lead to misinterpreted results in cell culture or animal model experiments.

Profos AG Announces Ultra High-Quality EndoGrade™ Ovalbumin

Readers who follow TNI's coverage of medical research will already be familiar with the important role of ovalbumin, a glycoprotein that is the main ingredient in egg whites, as a model allergen for studying airway hyper-responsiveness (AHR) in asthmatic and allergic conditions. Research like this is especially sensitive to microbiological contamination, especially in the form of lipopolysaccharides (LPS), also called endotoxins, which can fully activate en-

by avoiding the unwanted side effects of endotoxin stimulation.

According to Dr. Stephanie Steck, Profos' Product Manager for EndoGrade™ Ovalbumin, the back story behind this new source of ultra high-quality ovalbumin is crucial to understanding why Profos has become a global market leader in high-quality endotoxin-free products. The reason is EndoTrap®, a proprietary endotoxin removal

system (based on antibodies and DNA) without the need for additional incubation and with highest recovery rates currently available. Available in two slightly different versions (EndoTrap® red and EndoTrap® blue), EndoTrap® is an affinity chromatography system based on highly specific protein ligands that bind to a conserved region of LPS for most Gram-negative bacteria.

EndoTrap® can be regenerated and reused several times without losing its ability to efficiently bind LPS. And because it's designed as a user-friendly flow-through system, EndoTrap®, requires no special training or equipment to operate and generates rapid results. Obviously, says Profos, EndoTrap®, can easily be scaled up for laboratory research and large-scale applications, as evidence by the company's own production of EndoGrade™ Ovalbumin.

The company behind these innovative solutions, Germany's Profos AG, was founded in 2000 as a spin-off of the University of Regensburg's Institute of Biophysics and Physical Biochemistry. The company's core competency lies in the exploitation of bacteriophage biology for pharmaceutical, diagnostic and research application. With EndoGrade™ Ovalbumin and its proprietary EndoTrap® system, Profos has

taken significant steps on its path to becoming a global market leader in the field of endotoxin removal systems and high-quality endotoxin-free products. A further step will be the launch of EndoTrap® Industrial, especially developed for biomanufacturing process. The launch is planned within the next few months.

Look for Profos at Analytica 2008 (April 1-4 in München) in Hall A3, Stand 259/360. ■



EndoGrade™ Ovalbumin

dothelial cells in an in-vitro assay and falsify research results.

Profos' EndoGrade™ Ovalbumin keeps endotoxin concentrations below 1 EU/mg, making it for all practical purposes free of microbiological contamination. At this extraordinary level, the product gives researchers the long sought for ability to ensure accurate results

product that is the secret behind the ability of Profos to provide ovalbumin – and other products still in development – with the lowest possible levels of endotoxins.

With EndoTrap®, Profos has pioneered an innovative system for removing LPS from aqueous biological solutions (e.g., proteins, antibodies, pep-



EndoTrap®



Profos AG
Josef-Engert-Str. 11
D-93053 Regensburg
Tel. (+49) 941 942 62 -0
Fax (+49) 941 942 62 20
eMail: info@profos.de
www.profos.de